Kairos Pharma Ltd Dossier - Source-backed chat

Kairos Pharma Ltd

KAPANYSE

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.41

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $1.56Price as of 2 Oct 2026

Data confidenceNot applicable

Market Cap $5.3M

Enterprise Value $2.7M

Shares Outstanding 3.4M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Kairos Pharma, Ltd. (KAPA) is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapeutics that reverse drug resistance and immune suppression. While the company faces significant near-term liquidity constraints and a going concern warning, its clinical pipeline presents high-upside potential. The lead candidate, ENV-105, has demonstrated an impressive 86% clinical benefit rate in Phase 2 trials for metastatic castration-resistant prostate cancer. Furthermore, the strategic acquisition of exclusive worldwide rights to CL-273 and CL-741 from Celyn Therapeutics significantly expands its footprint in the multi-billion-dollar lung cancer market. The investment thesis is built on the potential of these clinical assets to achieve major milestones in 2026, supported by non-dilutive funding and strategic clinical partnerships.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets2 analysts · as of 18 Aug 2026

Low · most bearish analyst$4.00

Mean target$8.00

High · most bullish analyst$12.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

Clinical trials for ENV-105 experience significant delays or unfavorable safety readouts, stalling the pipeline. The company fails to secure additional non-dilutive funding or strategic partnerships, forcing highly dilutive equity raises at depressed share prices or leading to severe liquidity distress under its going concern status.

Base CaseCentral scenario

The company successfully advances its lead candidate, ENV-105, through Phase 2 trials, delivering positive safety and efficacy readouts by Q3 2026. Concurrently, Kairos initiates the Phase 1 trial for CL-741 in EGFR-mutated lung cancer. The company manages its tight liquidity by utilizing its At-the-Market (ATM) equity program and securing additional non-dilutive clinical funding, avoiding severe dilution while maintaining operational momentum.

Bull CaseUpside scenario

The company successfully completes Phase 2 trials for ENV-105 with outstanding efficacy, leading to a lucrative licensing deal or co-development partnership with a major pharmaceutical company (e.g., Bayer). Concurrently, the rapid initiation of Phase 1 trials for CL-741 and CL-273 establishes Kairos as a leading developer of therapies targeting oncology drug resistance, driving significant valuation upside.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong clinical efficacy with ENV-105 showing an 86% clinical benefit rate in Phase 2 prostate cancer trials.
Strategic asset acquisition of CL-273 and CL-741, targeting the high-value EGFR-mutated and c-MET-driven lung cancer markets.
Established clinical partnerships and consortia, notably with Cedars-Sinai Medical Center, Mayo Clinic, and Stanford, to accelerate trial execution.
Access to non-dilutive funding, including Department of Defense grants, to support biomarker and clinical studies.

Key Investment Risks

Going concern risk due to recurring losses, lack of product revenue, and limited cash reserves ($3.68M as of March 31, 2026).
High risk of shareholder dilution from the potential utilization of the ATM program, equity line of credit, or proposed equity plan increases.
Clinical development risk inherent in early-stage oncology therapeutics, where trial failures or delays are common.

Thesis Invalidation Triggers

Negative or inconclusive clinical data readouts for ENV-105 in prostate or lung cancer trials.
Inability to secure additional financing or strategic partnerships, leading to insolvency or a halt in clinical operations.
Failure to complete the acquisition or successfully initiate clinical development of the Celyn Therapeutics assets (CL-273 and CL-741).

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.